Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and
commercialization of next-generation multifunctional biotherapeutics, is pleased to announce the detailed voting results on the
items of business considered at its Annual General and Special Meeting of Shareholders held on June 7, 2018 (the
“Meeting”).
Shareholder Voting Results
The Shareholders voted on the following matters at this year’s Meeting.
Proposal 1 – Election of Directors
The nominees listed in Zymework’s Management Information Circular dated May 2, 2018 (the “Circular”) were elected as
Directors of the Company. Detailed results of the votes are set out below:
| |
|
|
|
|
|
|
|
|
| Proposal 1 |
|
|
|
Outcome of the
Vote
|
|
|
|
Votes by Ballot |
| Election of Directors |
|
|
|
|
|
|
Votes For |
|
|
|
Votes Withheld |
| Dr. Ali Tehrani |
|
|
|
Carried |
|
|
|
11,899,212
(98.82%) |
|
|
|
141,718
(1.18%) |
| Nick Bedford |
|
|
|
Carried |
|
|
|
11,899,174
(98.82%) |
|
|
|
141,756
(1.18%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal 2 – Appointment of Auditors
The vote was carried for the Appointment of the Auditors, KPMG LLP. Detailed results of the votes are set out below:
| |
|
|
|
|
|
|
|
|
| Proposal 2 |
|
|
|
Outcome of the
Vote
|
|
|
|
Votes by Ballot |
| |
|
|
|
|
|
|
Votes For |
|
|
|
Votes Withheld |
| Appointment of KPMG LLP |
|
|
|
Carried |
|
|
|
17,624,971
(99.72%) |
|
|
|
49,430
(0.28%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal 3 – Amendment and Restatement of Stock Option Plan
The vote was carried on the resolution approving the proposed amendments to Zymeworks’ stock option plan, as more particularly
described in the Circular. Detailed results of the votes are set out below:
| |
|
|
|
|
|
|
|
|
| Proposal 3 |
|
|
|
Outcome of the
Vote
|
|
|
|
Votes by Ballot |
| |
|
|
|
|
|
|
Votes For |
|
|
|
Votes Against |
|
Amendment and
Restatement of Stock
Option Plan
|
|
|
|
Carried |
|
|
|
10,333,495
(85.82%) |
|
|
|
1,707,435
(14.18%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal 4 – Amendment and Restatement of Employee Stock Purchase Plan
The vote was carried on the resolution approving the proposed amendments to Zymeworks’ employee stock purchase plan, as more
particularly described in the Circular. Detailed results of the votes are set out below:
| |
|
|
|
|
|
|
|
|
| Proposal 3 |
|
|
|
Outcome of the
Vote
|
|
|
|
Votes by Ballot |
| |
|
|
|
|
|
|
Votes For |
|
|
|
Votes Against |
|
Amendment and
Restatement of Employee
Stock Purchase Plan
|
|
|
|
Carried |
|
|
|
11,901,972
(98.85%) |
|
|
|
138,958
(1.15%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Full details of all proposals are fully described in the Circular available on the Company’s profile on SEDAR at www.sedar.com, and on EDGAR at www.sec.gov , and the detailed results of voting on each proposal are included in
the Report of Voting Results filed on SEDAR and on EDGAR.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of
next-generation multifunctional biotherapeutics. Zymeworks’ suite of complementary therapeutic platforms and its fully integrated
drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product
candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase
1 clinical trial. The company’s second product candidate, ZW49, capitalizes on the unique design and antibody framework of ZW25 and
is a bispecific antibody-drug conjugate, or ADC, armed with the company’s proprietary ZymeLink™ cytotoxic payload. Zymeworks is
also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other
therapeutic areas. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through
multiple strategic partnerships with global biopharmaceutical companies.
Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D., 604-678-1388
ir@zymeworks.com
or
Media Inquiries:
Angela Bitting, 925-202-6211
a.bitting@comcast.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20180607006346/en/